جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

32 مُخرَج نتائج البحث عن «ADME»

مقالوصول مغلق20262استشهاد· Semantic Scholar

DFT and Molecular Dynamics Guided Pharmacokinetic Evaluation of Phenyl Styryl Ketone Derivatives as Potential MAO‐B Inhibitors

ChemistrySelect · مجلد 11 (2)

ABSTRACT This research explores the capacity of phenyl styryl ketone derivatives to inhibit monoamine oxidase B (MAO‐B), a key enzyme associated with neurodegenerative disorders. From frontier molecular orbital (FMO) studies, reactivity parameters of the drug candidates were found out. Ligands were submitted to absorption, digestion, metabolism, excretion, and toxicity (ADMET) analysis to ensure their potential drugability and safety. To understand the electronic description of ligand interaction, natural bond orbital (NBO) analysis was conducted, and the presence of heteroatoms was proven crucial. The reduced density gradient (RDG) studies, together with molecular electrostatic surface potential (MESP) analysis, were able to provide the ligand's active sites and nature of interaction. Docking studies were conducted to study the interaction between the protein (P) and ligand (L) at the MAO‐B catalytic region, alongside a comparison with safinamide, a recognized MAO‐B inhibitor. Molecular dynamics (MD) simulations were utilized to examine the protein–ligand complex (PLC). The molecular mechanics Poisson–Boltzmann surface area (MM‐PBSA) method was applied to predict the binding affinity and interaction. We also analyzed structural stability, solvation, and decomposition. Of the four ligands examined, CHA_1.4 is found to be the most efficient. The contact map method was useful in identifying the key amino acids; in all the complexations we have considered, TYR398 has interacted most with the drug candidates. The finding was in agreement with the decomposition profile of the PLC. For the principal component analysis (PCA), topology formats and 100 ns MD trajectories are used to learn more about how proteins fold. Replicates were also done to validate the reported study and are represented as box‐whisker plots. The study's findings provide valuable insights for the development of new MAO‐B inhibitors.

monoamine oxidase B inhibitorsmonoamine oxidase Bneurodegenerative diseasesfrontier molecular orbitals
مقالوصول مغلق2026

Integrated In Silico and In Vitro Discovery of a VEGFR-2-Targeted Anticancer Benzanilide Lead

Journal of Computational Biophysics and Chemistry · 1-20

The development of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors remains a promising strategy for anticancer therapy targeting tumor angiogenesis. In the study at hand, a novel benzanilide-based derivative, ACEB-Cl, was rationally designed by assimilating fundamental pharmacophoric characteristics essential for VEGFR-2 inhibition. ACEB-Cl was evaluated using a comprehensive approach that combined computational modeling, synthesis, and in vitro biological assessment. Density functional theory (DFT) calculations revealed a favorable electronic profile, with distinct nucleophilic and electrophilic regions that could support potential interactions within the VEGFR-2 binding pocket. Docking and molecular dynamics (MD) simulations suggested stable binding of ACEB-Cl within the ATP-binding pocket, supported by strong hydrophobic interactions and favorable binding free energy ([Formula: see text] kcal/mol). Following synthesis, ACEB-Cl confirmed potent anti-VEGFR-2 activity in an ELISA-based assay (IC[Formula: see text]M), showing higher potency than sorafenib. Western blot analysis further confirmed significant downregulation of phosphorylated VEGFR-2 in MDA-MB-231 cells. In vitro cytotoxicity studies revealed selective anticancer activity, with reduced toxicity toward normal Vero cells and favorable selectivity indices. Mechanistically, ACEB-Cl triggered G0/G1 phase arrest and significantly increased apoptotic cell death, highlighting its ability to suppress cancer cell proliferation. Additionally, ADMET and toxicity estimations indicated a balanced pharmacokinetic and safety profile, with improved solubility, acceptable absorption, and reduced toxicity risks compared to sorafenib. Overall, this integrated study pinpointed ACEB-Cl as a promising VEGFR-2-targeted anticancer lead compound with strong inhibitory potency and a clearly defined mechanism of action, supporting its progression for further improvement.

VEGFR-2 inhibitorsbenzanilidestumor angiogenesisanticancer drug discovery
مقالوصول مغلق2026

Development of a Novel Benzanilide Derivative Targeting VEGFR-2: Computational Modeling and In Vitro Anticancer Validation

Journal of Computational Biophysics and Chemistry · 1-20

The pursuit of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors continues to be a key approach in anticancer drug discovery. In this context, a new benzanilide-based derivative, Z-CMPBC, was designed following essential VEGFR-2 pharmacophoric requirements and investigated through combined computational and biological approaches. Density functional theory (DFT) calculations at the B3LYP/6-31[Formula: see text]G(d, p) level indicated favorable electronic characteristics, including balanced chemical hardness and pronounced electrophilicity, suggesting a strong propensity for interaction within kinase active sites. Molecular docking, supported by 200 ns molecular dynamics simulations, demonstrated stable accommodation of the compound within the VEGFR-2 binding pocket. Binding free energy calculations using the MM-GBSA method revealed a significant interaction profile ([Formula: see text] kcal/mol), mainly governed by van der Waals forces and persistent hydrophobic interactions with critical residues. Biological assessment confirmed potent VEGFR-2 inhibition, with an IC[Formula: see text] value of [Formula: see text]M, closely comparable to sorafenib ([Formula: see text]M). Western blot analysis further verified a reduction in phosphorylated VEGFR-2 (pY1054/Y1059) levels in MCF-7 cells, supporting effective intracellular kinase inhibition. Additionally, Z-CMPBC exhibited pronounced cytotoxicity, particularly against MCF-7 breast cancer cells (IC[Formula: see text]M), along with a high selectivity index ([Formula: see text]) relative to normal Vero cells. Flow cytometry analysis demonstrated induction of G0/G1 phase arrest, accompanied by enhanced apoptotic activity (34.05%) compared to untreated cells. In silico ADMET and toxicity predictions suggested acceptable pharmacokinetic behavior and safety characteristics. Overall, these findings highlight Z-CMPBC as a promising VEGFR-2 inhibitor with potential for further development as an anticancer agent.

VEGFR-2 inhibitorsanticancer drug discoverykinase inhibitorsMCF-7 cells
مقالوصول مغلق202510استشهاد· Semantic Scholar

Integrated Computational and Experimental Discovery of a Promising Xanthine Derivative with Anticancer Potential Targeting EGFR

Current Cancer Drug Targets · مجلد 25

INTRODUCTION: Epidermal Growth Factor Receptor (EGFR) is a well-established therapeutic target in cancer treatment. In this study, a novel N-phenylacetamide derivative of theobromine, designated as T-1-PA, was designed as a potential semisynthetic EGFR inhibitor. METHOD: The 3D structure, stability, and electronic reactivity of T-1-PA were determined using Density Functional Theory (DFT) analyses. Molecular docking, molecular dynamics (MD) simulations, Molecular Mechanics Generalized Born Surface Area (MM-GBSA), Protein-Ligand Interaction Profiler (PLIP), and Principal Component Analysis of Trajectories (PCAT) were employed to evaluate the binding affinity and inhibitory potential of T-1-PA against EGFR. Computational ADMET profiling was conducted to predict drug-likeness and safety. Subsequently, T-1-PA was semisynthesized and subjected to in vitro biological evaluation. RESULTS: Computational analyses demonstrated a strong binding affinity of T-1-PA to EGFR. The compound exhibited favorable ADMET properties. In vitro assays revealed potent EGFR inhibition with an IC₅₀ of 0.736 ± 0.005 μM. T-1-PA also inhibited the proliferation of HepG2 and MCF7 cancer cell lines with IC₅₀ values of 0.88 ± 0.01 μM and 1.13 ± 0.01 μM, respectively. Flow cytometry analysis indicated induction of apoptosis and G1 phase cell cycle arrest in HepG2 cells. Additionally, T-1-PA significantly impaired HepG2 cell migration and wound-healing capacity. DISCUSSION: The results validate the computational predictions and highlight the anticancer potential of T-1-PA through EGFR inhibition and antiproliferative activity. The compound's favorable pharmacokinetic and safety profiles further support its therapeutic promise. CONCLUSION: T-1-PA is a promising semisynthetic compound with selective antiproliferative activity mediated via EGFR inhibition. These findings encourage further preclinical investigation of T-1-PA as a novel candidate for EGFR-targeted cancer therapy.

xanthine derivativestheobromineacetanilideEGFR inhibitors
مقالوصول مغلق20255استشهاد· Semantic Scholar

New Thiadiazole‐Benzenesulfonamide Hybrids as Dual B‐Raf/ VEGFR ‐2 Inhibitors With Promising Anti‐Hepatic Cancer Activity

Chemical Biology & Drug Design · مجلد 106 (1) · e70156-e70156

ABSTRACT A new group of thiadiazole‐benzenesulfonamide hybrids was designed, synthesized, and biologically evaluated as potential dual inhibitors targeting B‐Raf and VEGFR‐2 for cancer therapy. The cytotoxic activity of the synthesized derivatives was assessed against HepG2 and Huh7 liver cancer cell lines, where compound 7a exhibited the most potent activity with IC 50 values of 17.89 μM and 25.07 μM, respectively. The kinase inhibition assay revealed that 7a strongly inhibited both B‐Raf (IC 50 = 0.11 μM) and VEGFR‐2 (IC 50 = 0.15 μM), surpassing sorafenib in B‐Raf inhibition. Further mechanistic studies revealed that 7a induced G2/M phase arrest, with a significant increase in late apoptotic cells (57.08%) compared to the control group (0.15%), confirming its pro‐apoptotic effect. The apoptotic pathway was further validated by caspase‐3 activation, Bax upregulation, and Bcl‐2 downregulation. Computational analyses verified the effective binding of compound 7a to VEGFR‐2. These analyses included molecular docking, molecular dynamic (MD) simulations, molecular mechanics with generalized Born and surface area solvation (MM‐GBSA), protein‐ligand interaction fingerprints (ProLIF), principal component analysis (PCAT), and free energy landscape (FEL) studies. Additionally, DFT studies indicated 7a 's stability and reactivity. In silico ADMET predictions indicated that the derivatives had good absorption, were non‐mutagenic, non‐carcinogenic, and exhibited low toxicity risks compared to sorafenib. These findings suggest that the synthesized thiadiazole‐benzenesulfonamide hybrids, particularly 7a , represent promising dual BRAF/VEGFR‐2 inhibitors with potent anti‐cancer activity, warranting further optimization and preclinical evaluation.

BRAF inhibitorsVEGFR-2 inhibitorsdual kinase inhibitorsliver cancer
مقالوصول مغلق20253استشهاد

VEGFR-2-Targeted Semisynthetic Theobromine Derivative: A Computer-Aided Drug Design (CADD) Approach

Journal of Computational Biophysics and Chemistry · مجلد 25 (11) · 2043-2063

Angiogenesis plays a pivotal role in tumor progression, and VEGFR-2 is a well-established therapeutic target in cancer treatment. In this study, we report the design, semi-synthesis, and comprehensive evaluation of a novel theobromine-based VEGFR-2 inhibitor, T-1-BHEPA [([Formula: see text]-[Formula: see text]-(4-(1-(2-benzoylhydrazono)ethyl)phenyl)-2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1[Formula: see text]-purin-1-yl)acetamide]. A structure-based computer-aided drug design (CADD) approach was employed, beginning with pharmacophore modeling, followed by in-depth computational validation. The binding affinity of T-1-BHEPA to VEGFR-2 was examined through molecular docking, 400 ns molecular dynamics (MD) simulations, MM-GBSA binding energy calculations, and protein–ligand interaction fingerprinting (ProLIF) interaction analysis, all of which confirmed a strong and stable interaction with the VEGFR-2 active site. DFT calculations indicated T-1-BHEPA’s stability and reactivity. Before semi-synthesis, in silico ADMET evaluations highlighted good solubility, nonhepatotoxicity, low CYP2D6 interaction and noncarcinogenic potential, along with a favorable chronic toxicity profile. Consistent with these predictions, T-1-BHEPA exhibited potent in vitro VEGFR-2 inhibition (IC 50 [Formula: see text] 0.059 ± 0.006 [Formula: see text]M), comparable to sorafenib (IC 50 [Formula: see text] 0.045 ± 0.006 [Formula: see text]M). T-1-BHEPA demonstrated selective cytotoxicity against a panel of cancer cell lines, with pronounced activity against MDA-MB-231 (IC 50 [Formula: see text] 11.64 ± 1.0 [Formula: see text]M), and a high selectivity index (SI > 6.7) over normal WI-38 cells. Cell cycle analysis revealed G2/M phase arrest, while apoptosis assays confirmed significant increases in early and late apoptotic populations. These effects were further supported by molecular markers, including elevated caspase-3, upregulation of Bax and downregulation of Bcl-2, consistent with activation of the intrinsic apoptotic pathway. Overall, T-1-BHEPA represents a rationally designed and biologically validated VEGFR-2 inhibitor with promising anticancer efficacy and safety, warranting further preclinical development.

VEGFR-2 inhibitorstheobromine derivativesangiogenesiscancer
مقالوصول مغلق20247استشهاد· Semantic Scholar

Novel Thiazolidine‐2,4‐Dione Derivatives as Potential VEGFR‐2 Inhibitors: Synthesis, Biological Testing, and in Silico Studies

ChemistrySelect · مجلد 9 (11)

Abstract In this work novel 2,4‐dioxothiazolidine‐derived compounds targeting VEGFR‐2 were designed and synthesized. Such compounds were evaluated for their anti‐proliferative and VEGFR‐2 inhibitory abilities. Compound 17 specifically demonstrated the strongest anti‐proliferative activity against the HCT‐116 cell line, with an IC 50 value of 10.09 μM. Additionally, compounds 15 , 18 , and 19 revealed good anti‐proliferative effects with IC 50 values of 12.46, 16.87, and 12.35 μM, respectively. Compound 17 demonstrated potent anti‐VEGFR‐2 efficacy, with an IC 50 value of 0.068 μM, which was comparable to sorafenib (IC 50 value of 0.058 μM). Compound 17 induced apoptosis in HCT‐116 cancer cells and caused G0‐G1 phase cell cycle arrest. Furthermore, it upregulated BAX levels (5.1‐fold) and downregulated Bcl‐2 levels (4.2‐fold), indicating its pro‐apoptotic effects. Compound 17 also increased caspase‐8 and caspase‐9 levels by 3.3‐fold and 4.7‐fold, respectively, compared to the control. The computational studies provided insights into the kinetic, structural properties, and binding mode of the VEGFR‐2‐ 17 complex. The DFT calculations elucidated compound 17 ′s structural and electronic properties, while computational ADMET and toxicity tests suggested acceptable degrees of drug‐likeness potential for the synthesized compounds. Our findings suggest that compound 17 holds promise as a potent apoptotic VEGFR‐2 inhibitor and may guide future efforts in developing new anticancer drugs.

thiazolidine-2,4-dione derivativesVEGFR-2 inhibitorsantiproliferative activityHCT116 cells
مقالوصول مغلق20244استشهاد· Semantic Scholar

In-silico and in-vitro evaluation of antifungal bioactive compounds from Streptomyces sp. strain 130 against Aspergillus flavus

Journal of Biomolecular Structure and Dynamics · مجلد 43 (12) · 6045-6063

Streptomyces spp. are considered excellent reservoirs of natural bioactive compounds. The study evaluated the bioactive potential of secondary metabolites from Streptomyces sp. strain 130 through PKS-I and NRPS gene-clusters screening. GC-MS analysis was done for metabolic profiling of bioactive compounds from strain 130 in the next set of experiments. Identified antifungal compounds underwent ADMET analyses to screen their toxicity. All compounds’ molecular docking was done with the structural gene products of the aflatoxin biosynthetic pathway of Aspergillus flavus. MD simulations were utilized to evaluate the stability of protein-ligand complexes under physiological conditions. Based on the in-silico studies, compound 2,4-di-tert butyl-phenol (DTBP) was selected for in-vitro studies against Aspergillus flavus. Simultaneously, bioactive compounds were extracted from strain 130 in two different solvents (ethyl-acetate and methanol) and used for similar assays. The MIC value of DTBP was found to be 314 µg/mL, whereas in ethyl-acetate extract and methanol-extract, it was 250 and 350 µg/mL, respectively. A mycelium growth assay was done to analyze the effect of compounds/extracts on the mycelium formation of Aspergillus flavus. In agar diffusion assay, zone of inhibitions in DTBP, ethyl-acetate extract, and methanol extract were observed with diameters of 11.3, 13.3, and 7.6 mm, respectively. In the growth curve assay, treated samples have delayed the growth of fungi, which signified that the compounds have a fungistatic nature. Spot assay has determined the fungal sensitivity to a sub-minimum inhibitory concentration of antifungal compounds. The study’s results suggested that DTBP can be exploited for antifungal-drug development.Communicated by Ramaswamy H. Sarma

StreptomycesAspergillus flavusantifungal agents2,4-di-tert-butylphenol